The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and allowed federal Medicare to pay for some GLP-1s for obesity treatment. Instead, ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Weight loss injections can be useful aids for people who are struggling to shed unwanted pounds. GLP-1 agonist jabs, like ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

A PRESENTER has candidly opened up on her “absolutely horrendous” experience while using Mounjaro. Danielle Mason, an ...

The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

Wegovy's launch in Thaliand comes nearly a month after Eli Lilly launched its obesity management drug Mounjaro in India at ...

Seizures of potentially dangerous weight loss drugs being sold on the black market in Scotland have soared as online dealers ...

Weight loss drugs like Ozempic, Zepbound and Wegovy are surging in popularity. Now, a new pill from Eli Lilly has taken a ...

Ozempic, along with its sister drug Wegovy, belongs to a new class of therapeutic known as GLP-1 receptor agonists. Originally developed for diabetes management, these medications have found a ...

The weight-loss drugs have grown in popularity, but are generally too expensive for most people to afford without insurance ...